Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Centessa Pharmaceuticals plcNASDAQ: CNTA

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$1.27B, compared with -$1.01B a year earlier.

Context

  • Retained earnings amounted to 197.2% of total assets at the end of Q1 FY2026, up 4.9 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -24.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.27B-6.7% QoQ
Last fiscal yearDec 2025
-$1.19B-20.0% YoY
Year agoMar 2025
-$1.01B-24.7% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.7%——
1 year-20.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(1.19B) USD
Year-over-year change
-20.0%

Retained Earnings vs competitors

How CNTA compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -24.7% is the 5th highest of 10, against a peer median of -37.6%.
  • Retained earnings amounts to 197.2% of total assets for CNTA, versus a peer median of 114.7%.
CNTA Competitors
Retained Earnings for CNTA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AAPGAscentage Pharma Group InternationalDec 2025CN¥0 CNY+100.0%—0.0%
CGONCG Oncology, Inc. Common stockSep 2026-$575.13M USD-70.3%—54.9%
CELCCelcuity Inc.Jun 2026-$580.6M USD-64.0%—70.1%
APGEApogee Therapeutics, Inc.Jun 2026-$721.72M USD-68.9%—54.0%
CNTACentessa Pharmaceuticals plcMar 2026-$1.27B USD-24.7%—197.2%
XENEXenon Pharmaceuticals Inc.Sep 2026-$1.57B USD-37.6%—130.8%
DYNDyne Therapeutics, Inc.Jun 2026-$1.7B USD-44.2%—170.6%
LEGNLegend Biotech CorporationSep 2026-$1.93B USD-0.0%—114.7%
ZLABZai Lab LimitedJun 2026-$2.73B USD-7.4%—254.0%
RAREUltragenyx Pharmaceutical Inc.Mar 2026-$4.72B USD-14.8%—364.0%
Peer median (excluding CNTA) —-37.6%—114.7%

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents595.08M393.64M128.03M383.22M61.3M
Short-term Investments00128.52M98.96M233.28M
Net Receivables16.81M26.72M39.15M45.3M60.34M
Inventory00000
Other Current Assets993K3.27M1.62M1.78M1.83M
Total Current Assets628.77M437.75M315.09M536.41M367.88M
Property, Plant & Equipment (Net)162K1.17M12.95M11.76M10.85M
Goodwill00000
Intangible Assets00000
Long-term Investments0000282.55M
Tax Assets03.51M29.65M26.59M24.78M
Other Non-current Assets699K1.88M2.55M2.05M1.44M
Total Non-current Assets861K6.56M45.15M40.39M319.62M
Total Assets629.64M444.31M360.25M576.8M687.5M
Account Payables8.07M13.84M11.82M7.14M7.58M
Short-term Debt00000
Tax Payables769K1.58M112K835K0
Deferred Revenue00000
Other Current Liabilities4.97M7.95M839K10.18M35.35M
Total Current Liabilities24.64M38.34M39.39M58M42.94M
Long-term Debt75.7M69.8M75.7M108.94M7.57M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities37.74M029K29K110.12M
Total Non-current Liabilities113.44M69.8M84.62M117.26M117.7M
Total Liabilities138.08M108.14M124M175.25M160.63M
Common Stock252K265K273K359K405K
Retained Earnings(385.65M)(601.86M)(752.95M)(988.7M)(1.19B)
Accumulated OCI688K(1.5M)1.49M4.21M2.71M
Other Stockholders Equity00000
Minority Interest00000
Total Equity491.55M336.17M236.24M401.55M526.86M
Total Debt75.7M69.8M84.59M117.23M7.57M
Net Debt(519.38M)(323.84M)(43.44M)(266M)(53.73M)

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.